Heterotopic ossification (HO) is defined as the formation of lamellar bone in extraskeletal soft tissues. HO can be a severe complication after hip arthroplasty but can possibly be prevented by postoperative treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or radiotherapy. Diclofenac is 1 of the most used drugs in HO prophylaxis because it is effective and long established. However, there is still no uniform therapy regimen in terms of duration, dose and side effect profile regarding the application of diclofenac in HO prevention. We have, therefore, conducted the first systematic review investigating diclofenac for HO prophylaxis after hip arthroplasty. The aim of this study is to assess the efficacy, dose and duration of diclofenac therapy in preventing HO after total hip arthroplasty (THA).
Methods:
According to the PRISMA Guidelines we performed a systematic literature search in EMBASE via Ovid, in MEDLINE via PubMed and in the Cochrane Library addressing all studies in English and German regarding the prophylaxis of HO with diclofenac after THA. We identified 731 potential studies and included 6 randomised controlled trials with 957 patients.
Results:
The studies were heterogeneous with regard to duration of therapy, dose, comparative group and follow-up period. The therapy duration ranged from 9 to 42 days, the applied diclofenac doses ranged from 75 mg to 150 mg daily. Patients treated with diclofenac showed a significant reduction in the total incidence of HO regarding to the Brooker Classification compared to placebo and no clinically relevant ossifications occured (Brooker III and IV).
Conclusions:
Diclofenac is efficacious in the prevention of HO and can be used routinely after THA. The existing data indicates that a minimum dose of 75 mg diclofenac per day started on the first postoperative day for a minimum of 9 days is needed to prevent HO with an acceptable incidence of side effects, such as gastrointestinal symptoms.
CholokDChungMTRanganathanK, et al. Heterotopic ossification and the elucidation of pathologic differentiation. Bone2018; 109: 12–21.
2.
NaraghiFFDeCosterTAMoneimMS, et al. Heterotopic ossification. Orthopedics1996; 19: 145–151.
3.
MolliganJMitchellRSchonL, et al. Influence of bone and muscle injuries on the osteogenic potential of muscle progenitors: contribution of tissue environment to heterotopic ossification. Stem Cells Transl Med2016; 5: 745–753.
4.
BalboniTAGobezieRMamonHJ.Heterotopic ossification: pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. Int J Radiat Oncol Biol Phys2006; 65: 1289–1299.
5.
ManriqueJAlijanipourPHellerS, et al. Increased risk of heterotopic ossification following revision hip arthroplasty for periprosthetic joint infection. Arch Bone Jt Surg2018; 6: 486–491.
6.
RosteiusTRauschVPätzholzS, et al. Incidence and risk factors for heterotopic ossification following periprosthetic joint infection of the hip. Arch Orthop Trauma Surg2019; 139: 1307–1314.
7.
NealBGrayHMacMahonS, et al. Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg2002; 72: 808–821.
8.
BoardTNKarvaABoardRE, et al. The prophylaxis and treatment of heterotopic ossification following lower limb arthroplasty. J Bone Joint Surg Br2007; 89: 434–440.
9.
ChaoSTLeeSYBordenLS, et al. External beam radiation helps prevent heterotopic bone formation in patients with a history of heterotopic ossification. J Arthroplasty2006; 21: 731–736.
10.
BrookerAFBowermanJWRobinsonRA, et al. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am1973; 55: 1629–1632.
11.
VasileiadisGIItoigawaYAmanatullahDF, et al. Intraobserver reliability and interobserver agreement in radiographic classification of heterotopic ossification. Orthopedics2017; 40: e54–e58.
12.
ShimonoKUchibeKKubokiT, et al. The pathophysiology of heterotopic ossification: Current treatment considerations in dentistry. Jpn Dent Sci Rev2014; 50: 1–8.
13.
ZychowiczME.Pathophysiology of heterotopic ossification. Orthop Nurs2013; 32: 173–177; quiz 8–9.
14.
RitterMAVaughanRB.Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg Am1977; 59: 345–351.
15.
AhrengartLLindgrenU.Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthop Relat Res1993; 293: 153–159.
16.
ZhuYZhangFChenW, et al. Incidence and risk factors for heterotopic ossification after total hip arthroplasty: a meta-analysis. Arch Orthop Trauma Surg2015; 135: 1307–1314.
17.
EggliSWooA.Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg2001; 121: 531–535.
18.
PavlouGSalhabMMurugesanL, et al. Risk factors for heterotopic ossification in primary total hip arthroplasty. Hip Int2012; 22: 50–55.
19.
MilakovicMPopovicMRamanS, et al. Radiotherapy for the prophylaxis of heterotopic ossification: a systematic review and meta-analysis of randomized controlled trials. Radiother Oncol2015; 116: 4–9.
20.
KanSLYangBNingGZ, et al. Nonsteroidal anti-inflammatory drugs as prophylaxis for heterotopic ossification after total hip arthroplasty: a systematic review and meta-analysis. Medicine (Baltimore)2015; 94: e828.
21.
WinklerSCraiovanBWagnerF, et al. Pathogenesis and prevention strategies of heterotopic ossification in total hip arthroplasty: a narrative literature review and results of a survey in Germany. Arch Orthop Trauma Surg2015; 135: 481–489.
22.
RaiszLG.Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med2001; 110(Suppl. 3A): 43s–45s.
23.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol2009; 62: e1–e34.
24.
EriksenMBFrandsenTF.The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc2018; 106: 420–431.
25.
HugKTAltonTBGeeAO.Classifications in brief: brooker classification of heterotopic ossification after total hip arthroplasty. Clin Orthop Relat Res2015; 473: 2154–2157.
26.
HigginsJPAltmanDGGøtzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
27.
WinklerSSpringorumHRVaitlT, et al. Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac. Int Orthop2016; 40: 673–680.
28.
SellSPhillipsOHandelM.No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty. Acta Orthop Scand2004; 75: 45–49.
29.
SellSWillmsRJanyR, et al. The suppression of heterotopic ossifications: radiation versus NSAID therapy–a prospective study. J Arthroplasty1998; 13: 854–859.
30.
WahlströmORistoODjerfK, et al. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand1991; 62: 419–421.
31.
ReisHJKüsswetterWSchellingerT.The suppression of heterotopic ossification after total hip arthroplasty. Int Orthop1992; 16: 140–145.
32.
KölblOKnellesDBarthelT, et al. Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial. Int J Radiat Oncol Biol Phys1998; 42: 397–401.
33.
JockheckMWillmsRVolkmannR, et al. Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac. Arch Orthop Trauma Surg1998; 117: 337–340.
34.
HandelMPhillipsOAndersS, et al. Dose-dependent efficacy of diclofenac-cholestyramine on pain and periarticular ossifications after total hip arthroplasty: a double-blind, prospective, randomised trial. Arch Orthop Trauma Surg2004; 124: 483–485.
35.
MacfarlaneRJNgBHGamieZ, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother2008; 9: 767–786.
36.
SchmidtSAKjaersgaard-AndersenPPedersenNW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am1988; 70: 834–838.
37.
JoiceMVasileiadisGIAmanatullahDF.Non-steroidal anti-inflammatory drugs for heterotopic ossification prophylaxis after total hip arthroplasty: a systematic review and meta-analysis. Bone Joint J2018; 100–B: 915–922.
38.
SøballeKChristensenFKristensenSS.Ectopic bone formation after total hip arthroplasty. Clin Orthop Relat Res1988; 228: 57–62.
39.
McMahonJSWaddellJPMortonJ.Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty1991; 6: 259–264.
40.
KnellesDBarthelTKarrerA, et al. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg Br1997; 79: 596–602.
41.
GarlandDE.A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop Relat Res1991; 263: 13–29.
42.
KölblOKnellesDBarthelT, et al. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. Int J Radiat Oncol Biol Phys1997; 39: 961–966.
43.
WurnigCAuerspergVBoehlerN, et al. Short term prophylaxis against heterotopic bone after cementless hip replacement. Clin Orthop Relat Res1997; 334: 175–183.
44.
CellaJPSalvatiEASculcoTP.Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty1988; 3: 229–234.
45.
van der HeideHJKoorevaarRTSchreursBW, et al. Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty1999; 14: 796–799.
46.
VavkenPDorotkaR.Economic evaluation of NSAID and radiation to prevent heterotopic ossification after hip surgery. Arch Orthop Trauma Surg2011; 131: 1309–1315.
47.
StraussJBChenSSShahAP, et al. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty. Int J Radiat Oncol Biol Phys2008; 71: 1460–1464.
48.
XueDZhengQLiH, et al. Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials. Int Orthop2011; 35: 3–8.
49.
van WalsemAPandhiSNixonRM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther2015; 17: 66.
50.
ZhuXTChenLLinJH.Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis. Medicine (Baltimore)2018; 97: e11649.
51.
BresalierRSSandlerRSQuanH, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med2005; 352: 1092–1102.
52.
WalkerC.Are all oral COX-2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac. Int J Rheumatol2018; 2018: 1302835.
53.
CroomKFSiddiquiMA.Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs2009; 69: 1513–1532.
54.
ArcqM.[Ectopic ossification: a complication after total hip replacement (author’s transl)]. Arch Orthop Unfallchir1973; 77: 108–131.
55.
HurlimannMSchiapparelliFFRotiglianoN, et al. Influence of surgical approach on heterotopic ossification after total hip arthroplasty - is minimal invasive better? A case control study. BMC Musculoskelet Disord2017; 18: 27.
56.
AlijanipourPPatelRPNaikTU, et al. Heterotopic ossification in primary total hip arthroplasty using the direct anterior vs direct lateral approach. J Arthroplasty2017; 32: 1323–1327.
57.
CookDJMulrowCDHaynesRB.Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med1997; 126: 376–380.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
